Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Roberto S Oliveri et al.|The Lancet|2021Cited by 337
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim Linton, Julie M. Vose, Umberto Vitolo et al.|The Lancet Haematology|2024Cited by 134
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation DataMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|Blood|2020Cited by 64
Restoring hemostasis: fibrinogen concentrate versus cryoprecipitateBrian Elliott, Louis M. Aledort|Expert Review of Hematology|2013Cited by 18